Joseph M. Davie, M.D., Ph.D.
Dr. Joseph Davie joined RiverVest’s scientific advisory board in May, 2001, bringing with him more than 40 years of experience in research and development in multiple therapeutic areas.
As former senior vice president of Research for Biogen, Inc. and senior vice president of Science and Technology at G.D. Searle & Co., Dr. Davie contributes deep insight into the pathways of successful drug development.
Dr. Davie’s corporate success is founded upon years of experimental research at Washington University, where he was a professor and head of the Department of Microbiology and Immunology. He has authored or co-authored more than 175 publications and has served on the editorial boards of prestigious journals including Diabetes, American Journal of Pathology and Journal of Molecular and Cellular Immunology.
In addition to RiverVest, Dr. Davie has served on the boards for Auxeris Therapeutics, Inc., Beyond Genomics, Inc., CV Therapeutics, Inc.; Curis, Inc.; Inflazyme Pharmaceuticals, Ltd., Keel Pharmaceuticals, Inc., Metaphore Pharmaceuticals, Inc., Neogenesis, Inc., Stratatech, LLC and Targeted Genetics, Inc. He is a member of National Council, Washington University School of Medicine in St. Louis.
Dr. Davie received his M.D. from Washington University School of Medicine and his Ph.D. in bacteriology from Indiana University.